Sclareol attenuates the development of atopic dermatitis induced by 2,4-dinitrochlorobenzene in mice
- 2 January 2019
- journal article
- research article
- Published by Taylor & Francis in Immunopharmacology and Immunotoxicology
- Vol. 41 (1) , 109-116
Abstract
Context: Atopic dermatitis is a common chronic inflammatory skin disease affecting up to 20% of children and 1% of adults worldwide. Treatment of atopic dermatitis include corticosteroids and immunosuppressants, such as calcineurin inhibitors and methotrexate. However, these treatments often bring about adverse effects including skin atrophy, osteoporosis, skin cancer, and metabolic syndrome. Objective: In this study, we evaluated the therapeutic effects and mechanisms of sclareol, a natural diterpene, on atopic dermatitis (AD)-like skin lesions induced by 2,4-dinitrochlorobenzene (DNCB) in mice. Materials and methods: To evaluate the effect of sclareol in vivo model, BALB/c mice were repeatedly injected intraperitoneally with sclareol (50 and 100 mg/kg) in 2,4-dinitrochlorobenzene (DNCB)-induced AD-like murine model. Major assays were enzyme-linked immunosorbent assay, histological analysis, flow cytometry, western blot analysis. Results: Intraperitoneal administration of sclareol (50 and 100 mg/kg) significantly attenuated AD-like symptoms, such as serum IgE levels, epidermal/dermal hyperplasia, and the numbers of infiltrated mast cells. In addition, systemic sclareol treatments reduced local pro-inflammatory cytokine concentrations, including IL-6, IL-1b, TNF-a, IL-4, IFN-g, and IL-17A, on AD-like lesions. Furthermore, we demonstrated that sclareol also suppressed T cell activation and the capability of cytokine productions (IFN-g, IL-4 and IL-17A) in response to DNCB stimulation. By examining the skin homogenate, we found that sclareol inhibited the AD-like severity likely through suppressions of both NF-kB translocation and phosphorylation of the MAP kinase pathway. Discussion and conclusions: Cumulatively, our results indicate that sclareol induced anti-inflammatory effects against the atopic dermatitis elicited by DNCB. Thus, sclareol is worth of being further evaluated for its potential therapeutic benefits for the clinical treatment of AD.Keywords
Funding Information
- iEGG and Animal Biotechnology Center
- The Feature Areas Research Center Program
- Higher Education Sprout Project
- Ministry of Education (MOE-107-S-, -E)
This publication has 24 references indexed in Scilit:
- Guidelines of care for the management of atopic dermatitisJournal of the American Academy of Dermatology, 2014
- TNF-α and Th2 Cytokines Induce Atopic Dermatitis–Like Features on Epidermal Differentiation Proteins and Stratum Corneum Lipids in Human Skin EquivalentsJournal of Investigative Dermatology, 2014
- Atopic dermatitis results in intrinsic barrier and immune abnormalities: Implications for contact dermatitisJournal of Allergy and Clinical Immunology, 2013
- Sclareol Exhibits Anti-inflammatory Activity in Both Lipopolysaccharide-Stimulated Macrophages and the λ-Carrageenan-Induced Paw Edema ModelJournal of Natural Products, 2012
- MAPKs and NF-κB differentially regulate cytokine expression in the diaphragm in response to resistive breathing: the role of oxidative stressAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2011
- Mast cells in atopic dermatitisCurrent Opinion in Immunology, 2009
- Animal Models of Atopic DermatitisJournal of Investigative Dermatology, 2009
- Cytokines and chemokines orchestrate atopic skin inflammationJournal of Allergy and Clinical Immunology, 2006
- Inhibition of Allergic Contact Dermatitis to DNCB But Not to Oxazolone in Interleukin-4-Deficient MiceJournal of Investigative Dermatology, 1999
- Aromatherapy in dermatologyClinics in Dermatology, 1998